P229 A retrospective database study of persistence and adherence in patients with asthma in the UK (UK-THIN): fluticasone furoate/vilanterol (FF/VI) versus beclometasone dipropionate/formoterol (BDP/FM)

Introduction and objectives A retrospective cohort analysis was conducted comparing persistence with, and adherence to, different inhaled corticosteroid/long-acting-β2-agonist (ICS/LABA) treatments by asthma patients. Here we report findings from patients initiating treatment with either FF/VI or BDP/FM, the latter administered either as flexible or fixed-dose. Methods Patients in the UK with data registered in The Health Improvement Network (THIN) database, who had a first prescription (index date) for any ICS/LABA between 1 January 2013–17 January 2018 (study period) and a prior asthma diagnosis, were included if they had ≥12 months medical history prior to index date plus ≥1 post-index ICS/LABA prescription. Patients were excluded if aged Results A total of 894 patients initiating FF/VI were matched to 3433 patients initiating BDP/FM. A higher proportion of patients persisted with FF/VI versus BDP/FM over 12 months (Kaplan-Meier analysis; figure 1). The likelihood of discontinuing treatment within 12 months after initiation was 31% lower for FF/VI than BDP/FM (index year-adjusted, hazard ratio=0.69; 95% CI 0.60–0.80; p Conclusion UK asthma patients initiating FF/VI were more likely to have higher persistence and better adherence to treatment than those initiating BDP/FM. GlaxoSmithKline plc. -funded study (209967/HO-18–19688).